Hepatitis C, table 4, Neurovisual Impairment: A Frequent Complication of Alpha-Interferon Treatment in Chronic Viral Hepatitis

table 4

Neurovisual Impairment: A Frequent Complication of Alpha-Interferon Treatment in Chronic Viral Hepatitis

table 4. P100 Latency and Central Visual Sensitivity at Baseline and at the End of Interferon Treatment of Eyes With Normal Pretreatment Visual and Neurophysiological Parameters

	Age (yrs)	Visual Evoked Responses (msec)		Central Visual Sensitivity (db)
		Baseline	End-of-Rx	Baseline	End-of-Rx

Eyes with normal end-of-treatment P100 latency (n = 59)	47.5 ± 15.3^*	117.0 ± 5.3	117.7 ± 5.2^,	25.4 ± 0.9^§^,	24.5 ± 1.6#^,
Eyes with abnormal end-of-treatment P100 latency (n = 15)	59.1 ± 11.0^*	117.5 ± 7.1^,	138.8 ± 8.7	24.4 ± 0.7^,^**	23.0 ± 1.2#^,^**

NOTE. Group and paired comparisons are indicated by symbols representing respective P values. Abbreviation: NS, not significant. ^* P = .007 (group comparison). P = NS. P < .0001. ^§ P = .008. #P = .002. ^** P = .016.